BRPI0912657A2 - produto farmacêutico compreendendo um antagonista de receptor muscarínico e um agonista beta2-adrenorreceptor - Google Patents

produto farmacêutico compreendendo um antagonista de receptor muscarínico e um agonista beta2-adrenorreceptor

Info

Publication number
BRPI0912657A2
BRPI0912657A2 BRPI0912657A BRPI0912657A BRPI0912657A2 BR PI0912657 A2 BRPI0912657 A2 BR PI0912657A2 BR PI0912657 A BRPI0912657 A BR PI0912657A BR PI0912657 A BRPI0912657 A BR PI0912657A BR PI0912657 A2 BRPI0912657 A2 BR PI0912657A2
Authority
BR
Brazil
Prior art keywords
beta2
receptor antagonist
pharmaceutical product
muscarinic receptor
adrenoreceptor agonist
Prior art date
Application number
BRPI0912657A
Other languages
English (en)
Portuguese (pt)
Inventor
Andrew Mather
Antonio Mete
Katherine Wiley
Rhonan Ford
Richard James Bull
Original Assignee
Astrazeneca Ab
Pulmagen Therapeutics Synergy
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0808710A external-priority patent/GB0808710D0/en
Priority claimed from GB0900563A external-priority patent/GB0900563D0/en
Application filed by Astrazeneca Ab, Pulmagen Therapeutics Synergy filed Critical Astrazeneca Ab
Publication of BRPI0912657A2 publication Critical patent/BRPI0912657A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
BRPI0912657A 2008-05-13 2009-05-12 produto farmacêutico compreendendo um antagonista de receptor muscarínico e um agonista beta2-adrenorreceptor BRPI0912657A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0808710A GB0808710D0 (en) 2008-05-13 2008-05-13 New combination 296
GB0900563A GB0900563D0 (en) 2009-01-14 2009-01-14 New combination
PCT/SE2009/050525 WO2009139708A1 (en) 2008-05-13 2009-05-12 PHARMACEUTICAL PRODUCT COMPRISING A MUSCARINIC RECEPTOR ANTAGONIST AND A β2-ADRENOCEPTOR AGONIST

Publications (1)

Publication Number Publication Date
BRPI0912657A2 true BRPI0912657A2 (pt) 2016-01-26

Family

ID=41318921

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0912657A BRPI0912657A2 (pt) 2008-05-13 2009-05-12 produto farmacêutico compreendendo um antagonista de receptor muscarínico e um agonista beta2-adrenorreceptor

Country Status (11)

Country Link
US (1) US20110190309A1 (enExample)
EP (1) EP2315589A4 (enExample)
JP (1) JP2011520877A (enExample)
KR (1) KR20110010725A (enExample)
CN (2) CN102908624A (enExample)
AU (1) AU2009247021B2 (enExample)
BR (1) BRPI0912657A2 (enExample)
CA (1) CA2723909A1 (enExample)
MX (1) MX2010012019A (enExample)
RU (1) RU2010147881A (enExample)
WO (1) WO2009139708A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200825084A (en) 2006-11-14 2008-06-16 Astrazeneca Ab New compounds 521
JP4837800B2 (ja) 2008-05-13 2011-12-14 アストラゼネカ・アクチエボラーグ ムスカリンｍ３受容体アンタゴニストとしてのキヌクリジン誘導体
GB201016912D0 (en) 2010-10-07 2010-11-24 Astrazeneca Ab Novel combination
KR101845257B1 (ko) 2011-02-07 2018-04-04 삼성전자주식회사 이미지 센서
JP2011195593A (ja) * 2011-06-30 2011-10-06 Astrazeneca Ab ムスカリンｍ３受容体アンタゴニストとしてのキヌクリジン誘導体

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL62140C (enExample) * 1942-12-16
GB8334494D0 (en) * 1983-12-24 1984-02-01 Tanabe Seiyaku Co Carbostyril derivatives
GR1001529B (el) * 1990-09-07 1994-03-31 Elmuquimica Farm Sl Μέ?οδος για την λήψη νέων 21-εστέρων της 16-17-ακετάλης της πρ να-1,4-διενο-3,20-διόνης.
US6223485B1 (en) * 1996-06-07 2001-05-01 Herman Miller, Inc. Wall panel system
KR20000029703A (ko) * 1996-07-29 2000-05-25 존 헤덴스트룀 아릴시클로알칸카르복실산에스테르,그것의용도,제약학적조성물및제조방법
US6613795B2 (en) * 1996-11-11 2003-09-02 Christian Noe Enantiomerically pure basic arylcycloalkylhydroxycarboxylic esters, processes for their preparation and their use in medicaments
WO2002096855A2 (en) * 2001-04-03 2002-12-05 Aryx Therapeutics Anticholinergic compounds and methods of use
US7056916B2 (en) * 2002-11-15 2006-06-06 Boehringer Ingelheim Pharma Gmbh & Co. Kg Medicaments for the treatment of chronic obstructive pulmonary disease
AR044134A1 (es) * 2003-05-02 2005-08-24 Novartis Ag Derivados de quinuclidina, metodo de preparacion y composiciones farmaceuticas.
GB0424284D0 (en) * 2004-11-02 2004-12-01 Novartis Ag Organic compounds
TW200738658A (en) * 2005-08-09 2007-10-16 Astrazeneca Ab Novel compounds
TW200738659A (en) * 2005-08-29 2007-10-16 Astrazeneca Ab Novel compounds
TW200825084A (en) * 2006-11-14 2008-06-16 Astrazeneca Ab New compounds 521
WO2008059239A1 (en) * 2006-11-14 2008-05-22 Astrazeneca Ab Novel compounds 514
TW200833670A (en) * 2006-12-20 2008-08-16 Astrazeneca Ab Novel compounds 569
GB0702456D0 (en) * 2007-02-08 2007-03-21 Astrazeneca Ab New combination
GB0702457D0 (en) * 2007-02-08 2007-03-21 Astrazeneca Ab New combination 666
GB0704000D0 (en) * 2007-03-01 2007-04-11 Astrazeneca Ab Salts 670
JP4837800B2 (ja) * 2008-05-13 2011-12-14 アストラゼネカ・アクチエボラーグ ムスカリンｍ３受容体アンタゴニストとしてのキヌクリジン誘導体
JP2011195593A (ja) * 2011-06-30 2011-10-06 Astrazeneca Ab ムスカリンｍ３受容体アンタゴニストとしてのキヌクリジン誘導体

Also Published As

Publication number Publication date
CN102088976A (zh) 2011-06-08
KR20110010725A (ko) 2011-02-07
AU2009247021B2 (en) 2012-06-07
US20110190309A1 (en) 2011-08-04
CN102908624A (zh) 2013-02-06
JP2011520877A (ja) 2011-07-21
EP2315589A1 (en) 2011-05-04
RU2010147881A (ru) 2012-06-20
CN102088976B (zh) 2012-12-26
EP2315589A4 (en) 2013-09-11
MX2010012019A (es) 2011-03-04
AU2009247021A1 (en) 2009-11-19
CA2723909A1 (en) 2009-11-19
WO2009139708A1 (en) 2009-11-19

Similar Documents

Publication Publication Date Title
LTC2379069I2 (lt) S1p receptoriaus agonisto dozavimas
BRPI0919539A2 (pt) antagonistas de receptor de opioide periférico e empregos dos mesmos
HUS1800027I1 (hu) Muszkarin receptor antagonista és béta-2-adrenoreceptor agonista kombinációi
DK2252581T3 (da) Kappa-selektiv opioidreceptorantagonist
DK2421849T3 (da) Diamidforbindelser med muscarinreceptorantagonist- og beta2-adrenoreceptoragonist-virkning
PT2317852E (pt) Formulações farmacêuticas contendo ligandos de recetor de dopamina
DK2692341T3 (da) Misbrugs-resistent lægemiddelformulering
DK2381986T3 (da) Lægemiddeladministrationsanordning
BRPI0910118A2 (pt) antagonistas de receptores do glucagon
DK2274030T4 (da) Lægemiddelafgivelsesanordning
BRPI0821683A2 (pt) Medicamento compreendendo um agonista parassimpatético e um antagonista simpatético ou agonista simpatético
EP2350060A4 (en) Melanocortin receptor AGONISTS
DK2081951T3 (da) Progesteron-receptorantagonister
BRPI0806966A2 (pt) Combinação de um antagonista de receptor muscarínico e um agonista beta-2-adrenoceptor
PL2379086T3 (pl) Preparat farmeceutyczny
DK2139890T3 (da) Perifere opioidreceptor-antagonister og anvendelser deraf
EP2154131A4 (en) INHIBITOR OF THE G-PROTEIN-COUPLED RECEPTOR AND PHARMACEUTICAL PRODUCT
BRPI0921654A2 (pt) formulação farmacêutica
DK2121630T3 (da) Hurtigt dissocierende dopamin-2-receptor-antagonister
BRPI0912657A2 (pt) produto farmacêutico compreendendo um antagonista de receptor muscarínico e um agonista beta2-adrenorreceptor
BRPI0918431A2 (pt) produto farmacêutico compreendendo um antagonista de receptor muscarínico e um agonista de beta-2-adrenoceptor.
FI20080348A0 (fi) Uudenlainen farmaseuttinen formulaatio
BRPI0908075A2 (pt) Antagonísta muscarínicos de pde4-duplos farmacóforos
DK2257534T3 (da) 3-aminoalkyl-1,4-diazepan-2-on-melanocortin-5-receptorantagonister
HK1158062A (en) Pharmaceutical product comprising a muscarinic receptor antagonist and a beta-2-adrenoceptor agonist

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 5A, 6A E 7A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2372 DE 21-06-2016 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.